Jpmorgan Chase & CO Kamada LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KMDA
# of Institutions
41Shares Held
5.8MCall Options Held
21KPut Options Held
0-
Phoenix Holdings Ltd. Givatayim, L31.65MShares$12.4 Million0.17% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny832KShares$6.22 Million0.01% of portfolio
-
Wells Fargo & Company San Francisco, CA610KShares$4.57 Million0.0% of portfolio
-
Y.D. More Investments LTD Ramat Gan, L3330KShares$2.47 Million0.18% of portfolio
-
Essex Investment Management CO LLC Boston, MA324KShares$2.42 Million0.52% of portfolio
About KAMADA LTD
- Ticker KMDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 44,800,500
- Market Cap $335M
- Description
- Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...